Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2025 10:16 ET | Source: BCC Research LLC

Brain Tumor Therapeutics Market to Grow at 11.1% CAGR Through 2030

The global market for brain tumor therapeutics was valued at $2.5 billion in 2024 and is projected to reach $4.7 billion by the end of 2030.
December 04, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
December 02, 2025 13:00 ET | Source: American Oncology Network

Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic

Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic
December 01, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis
November 25, 2025 08:30 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25,...
November 17, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

“Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” said James Nathanielsz, CEO of Propanc.
November 10, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

We are entering a transformative phase for the Company as we work on building our digital asset base and strengthening our balance sheet
November 04, 2025 07:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.
October 22, 2025 14:26 ET | Source: BCC Research LLC

Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030

Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Molecular Diagnostics: Technologies and Global Markets” is projected to grow from $23 billion in 2025 to...
October 17, 2025 14:06 ET | Source: BCC Research LLC

Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030

Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is...